DNA Probes-Based Diagnostics

DNA Probes-Based Diagnostics

Global DNA Probes-Based Diagnostics Market to Reach US$34.5 Billion by 2030

The global market for DNA Probes-Based Diagnostics estimated at US$18.3 Billion in the year 2023, is expected to reach US$34.5 Billion by 2030, growing at a CAGR of 9.5% over the analysis period 2023-2030. Infectious Diseases Application, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$20.4 Billion by the end of the analysis period. Growth in the Cancer Application segment is estimated at 10.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.9 Billion While China is Forecast to Grow at 8.9% CAGR

The DNA Probes-Based Diagnostics market in the U.S. is estimated at US$4.9 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.4 Billion by the year 2030 trailing a CAGR of 8.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.5% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR.

Global DNA Probes-Based Diagnostics Market - Key Trends and Drivers Summarized

DNA probes-based diagnostics are pivotal in identifying pathogens, genetic mutations, crucial for addressing the global increase in infectious diseases and advancing personalized healthcare. Technological advancements in genomic sequencing and analysis, such as real-time PCR and next-generation sequencing, enhance the speed and accuracy of DNA probes-based diagnostics, driving market growth. Personalized medicine demands tailored therapeutic strategies based on individual genetic information, with home-based DNA diagnostic technologies gaining prominence for their convenience and rapid results, particularly in infectious disease diagnosis.

DNA probes-based diagnostics play a critical role in identifying genetic variations that affect individual responses to different medications, thus enabling tailored therapeutic strategies. The push towards home-based DNA diagnostic technologies is part of a broader trend towards personalized and accessible healthcare. Beyond magnetic sample preparation, isothermal amplification, and LFAs, the industry continues to innovate with developments in microfluidics for automated sample preparation, miniaturized PCR for compact devices, and electrochemical detection methods that measure electrical signals from DNA. These technologies not only promise to enhance the ease and effectiveness of home diagnostics but also open new avenues for rapid disease monitoring and management directly by consumers.

The market for DNA probes-based diagnostics is poised for significant growth, driven by technological advancements, increased healthcare needs, and the rising emphasis on personalized medicine. As these diagnostics become more integrated with digital technologies and expand into new medical fields, they will likely become even more central to healthcare delivery worldwide, improving the speed and accuracy of myriad medical diagnostics and treatments. Integration with digital and mobile technologies expands the accessibility of DNA probes-based diagnostics, enabling remote data analysis and real-time monitoring outside traditional lab settings. Multiplex testing, capable of detecting multiple pathogens or genetic changes from a single sample, enhances efficiency in pandemic outbreaks and complex genetic testing. Automation and high-throughput systems increase diagnostic efficiency, essential for large-scale epidemiological studies and clinical trials, while reducing human error potential in laboratories.

Select Competitors (Total 46 Featured) -

• Abbott Molecular
• Beckman Coulter Inc.
• Becton, Dickinson and Company
• bioMérieux
• F. Hoffmann-La Roche Ltd.
• GE Healthcare Life Sciences
• Luminex Corporation
• QIAGEN N.V.
• Siemens Healthineers
• Thermo Fischer Scientific Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.